Collaborative Networks Driving Regulatory Transformation in Latin America
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
The National Administration of Drugs, Foods and Medical Devices (ANMAT) is an agency decentralized from the National Public Administration that was created by decree 1490/92.It cooperates in the protection of human health by assuring the quality of the products it regulates: drugs, foodstuff, medicinal products, diagnosis reagents, cosmetic products, dietary supplements and household cleaning products.Having a nationwide jurisdiction, it was created in August 1992 and ever since its group of professionals and technicians have worked with modern technology in order to efficiently fulfill the process of authorization, registration, standardization, vigilance and monitoring of the products used in the human medicine, food and cosmetic fields.Granted with an economic and financial autarky, in the technical and scientific field it is under the authority of the Ministry of Health Secretariat of Policies, Regulation and Institutes standards and guidelines. In this framework, ANMAT main objective is to guarantee that drugs, foodstuff, medical devices at the reach of the public be compliant in terms of efficacy (fulfillment of the therapeutic, nutritional or diagnostic objective), safety (high benefit/risk ratio) and quality (by meeting the citizens´ needs and expectations).
CONTACT DETAILS
Av. De Mayo 869, C1084AAD – CABA
Tel: +54 (11) 4340-0800
MSD’s Leonardo Semprun, writing in the June 2025 edition of DIA’s Global Forum magazine, reflects on some of the key lessons from the Latin America Town Hall at DIA Europe…
A roundup of some of the biggest stories coming out of Latin American pharma and healthcare, including Mexico’s move to speed up the drug review process; Sanfer’s acquisition of Columbia’s…
A roundup of top stories from Latin American pharma and healthcare, including the beginning of the Mexican government’s consolidated procurement of medicines; Libbs’ new biologics plant; Novo Nordisk’s USD 142.4…
An overview of some of the biggest news from Latin American pharma, including Onconic Therapeutics’ licensing deal with Laboratorios Sanfer for 19 LatAm countries; Lupin’s orphan drug partnership with Argentina’s…
A roundup of some of the latest stories coming out of Latin American pharma and healthcare, including Merck’s new distribution centre in Brazil; the region’s record dengue surge; Roemmers Laboratory’s…
Writing in the July 2023 edition of DIA’s Global Forum magazine, Mariana Abdala of Crystal Research outlines the vast room for improvement in Latin America’s clinical trial output, the region’s…
Japanese-headquartered Takeda has been undergoing a transformation in recent years, becoming the global leader in rare diseases with the acquisition of Shire in 2018 and divesting ‘non-core’ assets in OTC…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
While Bayer’s recent history has been dominated by the controversial Monsanto acquisition, the German firm will be hoping for a more straightforward next few years with a new leadership team…
Argentinian generics manufacturer Grupo Roemmers – which celebrated its 100-year anniversary in 2021 – has expanded steadily across the Latin America and Caribbean region since the mid-1970s with a successful…
Axios International has been designing and implementing access to healthcare solutions in collaboration with the pharmaceutical industry and other healthcare players across Latin America (LatAm), Europe, the Middle East, Africa,…
Maria Gabriela Pittis, Head of SAM (South Cone, Andean Region, Mexico & Central America and Caribbean) at Takeda, outlines the company’s significant presence in the cluster, its double digit growth…
See our Cookie Privacy Policy Here
